Early prediction of the sensitivity of warfarin in elderly patients by the fall in factor VIIc and protein C at the induction of treatment

Thrombosis Research

Volumn 109, Issue 5-6, 2003, Pages 287-291

  Bertola, Jean Pierre ^a   Mazoyer, Elisabeth ^a   Bergmann, Jean François ^a   Drouet, Ludovic ^a   Simoneau, Guy ^a   Mahé, Isabelle ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Factor VIIc; Protein C; Warfarin

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7C; CREATININE; PROTEIN C; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN;

ACCURACY; AGED; ANALYTICAL PARAMETERS; ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; CREATININE CLEARANCE; DEMOGRAPHY; DOSE CALCULATION; DRUG SENSITIVITY; FEMALE; FOLLOW UP; GENETIC REGULATION; HALF LIFE TIME; HEART ATRIUM FIBRILLATION; HUMAN; INTOXICATION; LABORATORY TEST; MAINTENANCE THERAPY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; STATISTICAL ANALYSIS; THROMBOEMBOLISM; TIME;

EID: 0038006804     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(03)00245-7     Document Type: Article

References (22)

1. Ansell J., Hirsh M.D., Dalen J., Bussey H., Anderson D., Poller L.et al. Managing oral anticoagulation therapy. Chest. 119:2001;22S-38S. [Suppl.].
2. Gurwitz J.H., Avron J., Ross-Degnan D., Choodnovskiy I., Ansell J. Aging and the anticoagulant response to warfarin therapy. Ann. Intern. Med. 116:1992;901-904.
3. Palareti G., Leali N., Coccheri S., Poggi M., Mannotti C., D'Angelo A.et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complication of Oral Anticoagulant Therapy. Lancet. 348:1996;423-428.
4. Landefeld C.S., Goldman L. Major bleeding in outpatient treated with warfarin incidence and prediction by factors known at the start of outpatient therapy. Am. J. Med. 87:1989;144-152.
5. Petitti D.B., Strom B.L., Melmon K.L. Prothrombin time ratio and others factors associated with bleeding in patients treated with warfarin. J. Clin. Epidemiol. 42:1989;759-764.
6. Levine M.N., Raskob G., Landefeld S., Kearon C. Hemorrhagic complication of anticoagulant treatment. Chest. 119:2001;108S-121S. [Suppl.].
7. Hylek E.M., Singer D.E. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann. Intern. Med. 120:1994;897-902.
8. Whittle J., Wicenheiser L., Venditti L.N. Is warfarin underused in the treatment of elderly persons with a trial fibrillation? Arch. Intern. Med. 157:1997;441-445.
9. Holford N.H. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose effect relationship. Clin. Pharmacokinet. 11:1986;483-504.
10. King S.Y., Joslin M.A., Raudibaugh K., Pienisaszeck H.J. Jr., Benedek I.H. Dose-dependent pharmacokinetics of warfarin in healthy volunteers. Pharm. Res. 12:1995;1874-1877.
11. Hirsh J., James E., Dalen J.E., Anderson D.R., Poller L., Bussey H.et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 119:2001;8S-20S. [Suppl.].
12. Gladman J.R., Dolan G. Effect of age upon the induction and maintenance of anticoagulation with warfarin. Postgrad. Med. J. 71:1995;153-155.
13. Fennerty A., Dolben J., Thomas P., Backhouse G., Bentley D.P., Campbell I.A.et al. Flexible Induction dose regimen for Warfarin and prediction of maintenance dose. Br. Med. J. (Clin. Res. Ed.). 288:1984;1268-1270.
14. Roberts G.W., Gallus A.S., Druskeit T., Miller C. Comparison of an age adjusted warfarin loading protocol with empirical dosing and Fennerty's protocol. Aust. N.Z. J. Med. 29:1999;731-736.
15. Weinstock D.M., Chang P., Aronson D., Kessler C.M. Comparison of plasma prothrombin and factor VIIc and urine prothrombin F1 concentration in patients on long-term warfarin therapy and those in the initial phase. Am. J. Hematol. 57:1998;193-199.
16. Margaglione M., Colaizzo D., Andrea G., Brancaccio V., Ciampa A., Grandone E.et al. Genetic modulation of oral anticoagulation with warfarin. Thromb. Haemost. 84:2000;775-778.
17. Aithal G.P., Day C.P., Kesteven P.J.L., Daly A.K. Association of polymorphism in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 353:1999;717-719.
18. Harrison L., Johnston M., Massicotte M.P., Crowther M., Moffat K., Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann. Intern. Med. 126:1997;133-136.
19. Fihn S.D., Callahan C.M., Martin D.C., Mc Donnel M.B. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann. Intern. Med. 124(11):1996;970-979.
20. Crowther M.A., Ginsberg J.B., Kearon C., Harrison L., Johnson J., Massicotte M.P.et al. A randomised trial comparing 5-mg and 10-mg warfarin loading doses. Arch. Intern. Med. 159:1999;46-48.
21. Weiss P., Soff G.A., Halkin H., Seligsohn U. Decline of proteins C and S and factors IIc, VIIc, IX and X during the initiation of warfarin therapy. Thromb. Res. 45:1987;783-790.
22. Jupe D.M., Peterson G.M., Coleman R.L., Mc Lean S. Warfarin dosage requirements: prospective clinical trial of method for prediction from the response to a single dose. Br. J. Clin. Pharmacol. 25:1988;607-610.